Expression Analysis of Long Non-coding RNAs in the Blood of Multiple Sclerosis Patients

Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system (CNS) with multiple genetic and environmental risk factors. Long non-coding RNAs (lncRNAs) have been recently reported to participate in the regulation of immune responses. Consequently, aberrant expression of lncRNAs has been suggested as an underlying cause of MS. In the present study, we evaluated the expression of three lncRNAs with putative roles in the regulation of immune response, namely TNF-α and heterogeneous nuclear ribonucleoprotein L (THRIL), Fas cell surface death receptor- antisense 1 (FAS-AS1), and plasmacytoma variant translocation 1 (PVT1) in circulating blood cells of 50 Iranian relapsing–remitting multiple sclerosis (RRMS) patients compared with healthy subjects by means of quantitative real-time polymerase chain reaction (PCR). We detected a significant downregulation of PVT1 and FAS-AS1 expressions in RRMS patients while a significant upregulation of THRIL in patients compared with controls (P < 0.001). Correlation analyses between lncRNA expression levels and clinical data of MS patients revealed no significant correlation between lncRNAs expression levels and Expanded Disability Status Scale (EDSS), a moderate correlation between PVT1 expression levels and duration of the disorder and no significant correlation between lncRNAs expression levels and age at onset. In addition, we demonstrated correlations between the expression levels of PVT1 and THRIL as well as expression levels of THRIL and FAS-AS1 in RRMS patients. In brief, we have demonstrated dysregulation of three lncRNAs in MS patients. Further studies are needed to explore the exact mechanisms by which these lncRNAs participate in regulation of immune responses.

[1]  H. Inoko,et al.  RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis , 2016, Journal of the Neurological Sciences.

[2]  Yuan Zhang,et al.  Long noncoding RNAs in innate immunity , 2015, Cellular and Molecular Immunology.

[3]  George D. Kalliolias,et al.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies , 2016, Nature Reviews Rheumatology.

[4]  Simon W. Jones,et al.  Transcriptional profiling identifies the long noncoding RNA plasmacytoma variant translocation (PVT1) as a novel regulator of the asthmatic phenotype in human airway smooth muscle , 2017, Journal of Allergy and Clinical Immunology.

[5]  T. Lehtimäki,et al.  Apoptosis-related molecules in blood in multiple sclerosis , 2008, Journal of Neuroimmunology.

[6]  A. Sayad,et al.  Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients , 2017, Neurological Sciences.

[7]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[8]  A. Sayad,et al.  Determination of cytokine levels in multiple sclerosis patients and their relevance with patients’ response to Cinnovex , 2017, Cytokine.

[9]  Ruoning Wang,et al.  MYC in Regulating Immunity: Metabolism and Beyond , 2017, Genes.

[10]  Fang Zhang,et al.  Expression Profile of Long Noncoding RNAs in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients , 2016, CNS neuroscience & therapeutics.

[11]  S. Ghafouri-Fard,et al.  The Role of Long Non-Coding RNAs in Breast Cancer. , 2016, Archives of Iranian medicine.

[12]  G. Macino,et al.  PVT1: A Rising Star among Oncogenic Long Noncoding RNAs , 2015, BioMed research international.

[13]  Zhonghan Li,et al.  The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL , 2013, Proceedings of the National Academy of Sciences.

[14]  W. Robinson,et al.  Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? , 2001, Arthritis and rheumatism.

[15]  T. Aune,et al.  Long non-coding RNAs in innate and adaptive immunity. , 2016, Virus research.

[16]  H. Inoko,et al.  HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis. , 2016, Pharmacogenomics.

[17]  M. Nasr-Esfahani,et al.  miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis , 2015, PloS one.

[18]  L. Kwak,et al.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma , 2014, Leukemia.

[19]  R. Podemski,et al.  Fas expression on T cells and sFas in relapsing‐remitting multiple sclerosis , 2003, Acta neurologica Scandinavica.